What's in Sarfez Pharmaceuticals, Inc.'s pipeline?

Sarfez Pharmaceuticals, Inc. has 5 drugs in our index: 1 marketed, 0 filed, 2 in Phase 3, 2 in Phase 2, 0 in Phase 1.

Which companies overlap with Sarfez Pharmaceuticals, Inc.'s portfolio?

Top competitors by shared drug class: Assistance Publique - Hôpitaux de Paris, B&A Therapeutics, China National Center for Cardiovascular Diseases, Ferrer Internacional S.A., Heart Care Foundation.

How do I subscribe to ongoing alerts?

Subscribe to /feed/company/sarfez-pharmaceuticals-inc.xml in any RSS reader. Every regulatory action and pipeline update lands in your feed.

Last reviewed 2026-05-16 · How we verify

Sarfez Pharmaceuticals, Inc. — Portfolio Competitive Intelligence Brief

Sarfez Pharmaceuticals, Inc. pipeline: 1 marketed, 0 filed, 2 Phase 3, 2 Phase 2. Recent regulatory actions, upcoming PDUFA, patent timeline, top competitor overlap.

1 marketed 0 filed 2 Phase 3 2 Phase 2 0 Phase 1 Live · 30-min refresh

Portfolio leaders (marketed + Phase 3 / filed)

Drug	Generic	Phase	Class	Target	Area
Immedate Release Torsemide Tablets	Immedate Release Torsemide Tablets	marketed	Loop diuretic	Na-K-2Cl cotransporter (NKCC2)	Cardiovascular
Torsemide and Spironolactone tablet	Torsemide and Spironolactone tablet	phase 3	Loop diuretic and potassium-sparing diuretic	Sodium-potassium-chloride cotransporter (NKCC2) and Aldosterone receptor	Cardiovascular
Torsemide Tablets and Spironolactone Tablets	Torsemide Tablets and Spironolactone Tablets	phase 3	Loop diuretic and potassium-sparing diuretic	Sodium-chloride cotransporter and Mineralocorticoid receptor	Cardiovascular

Therapeutic area mix

Cardiovascular · 5

Recent regulatory actions (last 90 days)

No regulatory actions in the last 90 days for this portfolio.

Upcoming PDUFA dates (next 180 days)

No PDUFA dates in the next 180 days for this portfolio.

Patent timeline (forward window)

No upcoming patent expiries for this portfolio.

Competitive overlap (companies sharing drug classes)

Assistance Publique - Hôpitaux de Paris · 1 shared drug class
B&A Therapeutics · 1 shared drug class
China National Center for Cardiovascular Diseases · 1 shared drug class
Ferrer Internacional S.A. · 1 shared drug class
Heart Care Foundation · 1 shared drug class
Instituto de Investigación Sanitaria Aragón · 1 shared drug class
Jose J Zaragoza, MD MSc · 1 shared drug class
Aspirus Heart and Vascular Institute-Research and Education · 1 shared drug class

Subscribe to ongoing alerts

Every new pipeline event for Sarfez Pharmaceuticals, Inc.:

Cite this brief

Drug Landscape (2026). Sarfez Pharmaceuticals, Inc. — Portfolio Competitive Intelligence Brief. https://druglandscape.com/ci/company/sarfez-pharmaceuticals-inc. Accessed 2026-05-16.